We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance
Read MoreHide Full Article
Pfizer, Inc. (PFE - Free Report) along with partner OPKO Health announced that the FDA has accepted the biologics license application (BLA) for somatrogon, its long-acting, once-weekly therapy to treat pediatric patients with growth hormone deficiency (GHD). The BLA was granted standard review and the FDA’s decision is expected in October 2021.
The BLA filing is based on data from a phase III study evaluating somatrogon dosed once-weekly in children with GHD. The study met its primary endpoint by showing non-inferiority of somatrogon injection compared to its own medicine Genotropin/somatropin injection (current standard of care) administered once daily, as measured by annual height velocity at 12 months. The top-line data showed that the least square mean was higher in the somatrogon group versus the somatropin group.
The efficacy of somatrogon seen in the study demonstrates its potential to reduce the current dosing frequency from once-daily to a single weekly injection.
Pfizer’s shares have declined 5.7% in the past year against the industry’s 3.6% increase.
Pfizer and OPKO signed the global deal for somatrogon in 2014, per which OPKO is mainly responsible for clinical development while Pfizer will take care of commercializing the product.
GHD is a rare disease characterized by insufficient secretion of somatropin, the hormone that causes growth, from the pituitary gland. Owing to this an individual’s height may remain short in adulthood and cause other health problems as well. Presently available treatments for GHD are NovoNordisk’s (NVO - Free Report) Norditropin, Roche’s (RHHBY - Free Report) Nutropin and Lilly’s (LLY - Free Report) Humatrope, among others.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance
Pfizer, Inc. (PFE - Free Report) along with partner OPKO Health announced that the FDA has accepted the biologics license application (BLA) for somatrogon, its long-acting, once-weekly therapy to treat pediatric patients with growth hormone deficiency (GHD). The BLA was granted standard review and the FDA’s decision is expected in October 2021.
The BLA filing is based on data from a phase III study evaluating somatrogon dosed once-weekly in children with GHD. The study met its primary endpoint by showing non-inferiority of somatrogon injection compared to its own medicine Genotropin/somatropin injection (current standard of care) administered once daily, as measured by annual height velocity at 12 months. The top-line data showed that the least square mean was higher in the somatrogon group versus the somatropin group.
The efficacy of somatrogon seen in the study demonstrates its potential to reduce the current dosing frequency from once-daily to a single weekly injection.
Pfizer’s shares have declined 5.7% in the past year against the industry’s 3.6% increase.
Pfizer and OPKO signed the global deal for somatrogon in 2014, per which OPKO is mainly responsible for clinical development while Pfizer will take care of commercializing the product.
GHD is a rare disease characterized by insufficient secretion of somatropin, the hormone that causes growth, from the pituitary gland. Owing to this an individual’s height may remain short in adulthood and cause other health problems as well. Presently available treatments for GHD are Novo Nordisk’s (NVO - Free Report) Norditropin, Roche’s (RHHBY - Free Report) Nutropin and Lilly’s (LLY - Free Report) Humatrope, among others.
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>